Butterfield 2001.

Methods	DESIGN Description: random‐assignment, placebo‐controlled, parallel arm, flexible dose, double‐blind BLINDING Participants: Unclear Assessors: Unclear Administrators: Unclear ALLOCATION CONCEALMENT Method: Unclear RANDOMISATION Method: Unclear
Participants	SAMPLE Description: 15 DSM‐IV PTSD, mean age: 43.2 years (26‐73), 14 women, 53.3% (8/15) MDD, most common comorbid diagnosis: GAD ‐ 64.3% (9/15), baseline severity on TOP‐8: olanzapine (19.3), placebo (21.8) SCREENING Primary diagnosis: SIP Comorbidity: MINI
Interventions	Description: olanzapine 5 mg/d ‐ 20mg/d (max. mean 14.1 mg/d) versys placebo (max. mean: 13.9mg/d) x 10 weeks
Outcomes	Primary outcomes: TOP‐8, SPRINT, Secondary outcomes: IES, DTS, CGI‐I, SDS, BAS, AIMS Data estimation: ITT (General linear model)
Notes	INDUSTRY SUPPORT Industry funded: Yes Medication provided by industry: No Any of the authors work for industry: No ADDITIONAL INFORMATION Drop‐out rates: 3/15 (20%) on olanzapine and 1/5 (20%) on placebo. Quality rating score: 24
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear